NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281
Predictive Oncology (NASDAQ: POAI) has made several advances in providing cancer treatment solutions. Its subsidiary, TumorGenesis, “specializes in technology that preserves a patient’s unique cancer tissue biological signatures, thereby allowing researchers to study cancer in the laboratory using samples that reflect actual tumors found in a patient,” reads a recent article. TumorGenesis’ transformational technology enables cell lines from patients to represent more than 90% of ovarian cancer cells, a significant improvement from the existing technologies, which can only represent 1% of ovarian tumor cells. “The result, simply stated, assists health providers in selecting the most effective drug to treat a specific patient’s unique cancer – personalized medicine at its finest.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer